Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma proteomic signature of fatty liver disease: The Rotterdam Study

4 Feb 2023

Abstract excerpt

BACKGROUND AND AIMS: Fatty liver disease (FLD) is caused by excess fat in the liver, and its global prevalence exceeds 33%. The role of protein expression on the pathogenesis of FLD and accompanied fibrosis and its potential as a disease biomarker is currently not clear. Hence, we aimed to identify plasma proteomics associated with FLD and fibrosis using population-based data. APPROACH AND RESULTS: Blood samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to Liver Disease Diagnosis and Treatment
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36738080
DOI: 10.1097/hep.0000000000000300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma proteomic signature of fatty liver disease: The Rotterdam StudyPMID 36738080Read ↗

A proteo-transcriptomic map of non-alcoholic fatty liver disease signaturesSemantic proximity Read ↗

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologiesSemantic proximity Read ↗

Multiomics study of nonalcoholic fatty liver diseaseSemantic proximity Read ↗

Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysisSemantic proximity Read ↗

Circulating Lipids Predict Mortality and Drive Immune Gene Regulation in Acute-on-Chronic Liver FailureSemantic proximity Read ↗

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liverSemantic proximity Read ↗

A paired liver biopsy and plasma proteomics study reveals circulating biomarkers for alcohol-related liver diseaseSemantic proximity Read ↗

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with Metabolically Dysfunction Associated Steatotic Liver DiseaseSemantic proximity Read ↗

LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2Semantic proximity Read ↗

Affinity proteomics-based non-invasive detection of clinically significant liver diseaseSemantic proximity Read ↗

Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 OutcomesSemantic proximity Read ↗

Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.